Company overview
What does National Vision Holdings, Inc. do?
National Vision Holdings, Inc. (EYE) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3851 (Ophthalmic Goods).
What does National Vision Holdings, Inc. do?
National Vision Holdings, Inc. (EYE) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3851 (Ophthalmic Goods).
What industry is National Vision Holdings, Inc. in?
Healthcare · Ophthalmic Goods
What was National Vision Holdings, Inc.'s latest reported revenue?
$498.8M for Q3 2026, from 10-Q filed Aug 13, 2026.
What changed in the latest comparable period?
Revenue increased +2.5% ($486.4M to $498.8M; Q2 2025 vs Q3 2026).
Business model (from the public record)
Belvedere describes the business using the issuer’s SEC classification and the company description extracted from public filings. Segment mix, customer identity, and recurring-versus-transactional revenue are shown only when those facts are identified in the filing extract—not inferred.
Healthcare · Ophthalmic Goods · United States
Financial profile
- Revenue
- $498.8M 10-Q · Q3 2026 · Filed Aug 13, 2026
- Revenue growth YoY
- +2.5% Belvedere calculation · 10-Q · Q3 2026 · Filed Aug 13, 2026
- Gross margin
- — Not identified in latest matched XBRL period
- Operating margin
- +4.3% Belvedere calculation · 10-Q · Q3 2026 · Filed Aug 13, 2026
- Net income
- $12.4M 10-Q · Q3 2026 · Filed Aug 13, 2026
- Operating cash flow
- — Not identified in latest matched XBRL period
- Capex
- — Not identified in latest matched XBRL period
- Belvedere FCF
- — Not identified in latest matched XBRL period
- FCF margin
- — Not identified in latest matched XBRL period
- Cash
- $36M 10-Q · Jul 4, 2026 · Filed Aug 13, 2026
- Debt
- $230.1M Belvedere calculation · 10-Q · Jul 4, 2026 · Filed Aug 13, 2026
- Net debt
- $194.1M Belvedere calculation · 10-Q · Jul 4, 2026 · Filed Aug 13, 2026
- Shares
- 79,058,038 10-Q · Jul 4, 2026 · Filed Aug 13, 2026
Balance sheet snapshot
Cash $36M. Identified debt $230.1M. Net debt $194.1M. Missing debt tags are not treated as a zero-debt capital structure.
Financial information is derived from public filings and other identified sources. Belvedere calculations may differ from company-defined non-GAAP measures. See methodology and source notes. Valuation multiples are omitted because a licensed market-data provider is not configured.
Latest filings
| Form | Filed | Period | Accession | Source |
|---|---|---|---|---|
| 10-Q | Aug 13, 2026 | Jul 4, 2026 | 0001628280-26-056493 | SEC |
| 8-K | Aug 12, 2026 | Aug 12, 2026 | 0001628280-26-055930 | SEC |
| 8-K | Jun 22, 2026 | Jun 17, 2026 | 0001628280-26-044630 | SEC |
| 8-K | Jun 3, 2026 | Jun 3, 2026 | 0001628280-26-040046 | SEC |
| 10-Q | May 14, 2026 | Apr 4, 2026 | 0001628280-26-034824 | SEC |
| 8-K | May 13, 2026 | May 13, 2026 | 0001628280-26-034360 | SEC |
| DEF 14A | May 4, 2026 | Jun 17, 2026 | 0001140361-26-018642 | SEC |
What changed
Each line is an arithmetic comparison of sourced facts. It is not a thesis.
Research view
Belvedere has not published an initiation or update on National Vision Holdings, Inc.. Universe inclusion is not a rating, a forecast, or coverage in the sell-side sense.
Research Radar
| Kind | Change | Explanation | Source | Date |
|---|---|---|---|---|
| Revenue | +2.5% | Revenue increased +2.5% ($486.4M to $498.8M; Q2 2025 vs Q3 2026). | 10-Q · RevenueFromContractWithCustomerExcludingAssessedTax | Aug 13, 2026 |
| Revenue acceleration | -4.0 pp | Quarterly revenue YoY growth moved from +6.6% to +2.5% (-4.0 percentage points). | 10-Q · BelvedereRevenueGrowthYoY | Aug 13, 2026 |
| Cash | $36.0M | Cash and cash equivalents were $36.0M as of the latest reported balance-sheet date. | 10-Q · CashAndCashEquivalentsAtCarryingValue | Aug 13, 2026 |
| Share count | $79.1M | Shares outstanding were 79,058,038 as of the latest reported date. | 10-Q · CommonStockSharesOutstanding | Aug 13, 2026 |
Rankings
- Healthcare Companies by Revenue Growth · rank 9 · +2.5%
Industry context
National Vision Holdings, Inc. is mapped to Healthcare (Ophthalmic Goods) from SIC metadata on the SEC submission. Mapping is a classification convenience, not a claim that every peer is economically comparable.
Belvedere Research Profile
This measures researchable information characteristics. It is not investment advice, a credit rating, or a buy/sell/hold recommendation.
Presence of core income-statement, cash-flow and balance-sheet concepts in SEC XBRL.
Comparable-period revenue history and operating-result availability.
Availability of margin, cash-flow and per-share concepts used in screening.
SEC periodic reports, current reports, proxy statement and website identified in submissions.
Distinct filing years in the current archive window plus comparable prior-period revenue.
Risks
Belvedere does not manufacture generic risk language. Material risks are those the issuer discloses in its periodic reports, particularly Item 1A of the latest Form 10-K.
A Form 10-K was not present in the current filing window.
Sources
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q3 2026
- Filed
- Aug 13, 2026
- Accession
- 0001628280-26-056493
- Concept
- RevenueFromContractWithCustomerExcludingAssessedTax
- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Q3 2026
- Filed
- Aug 13, 2026
- Accession
- 0001628280-26-056493
- Concept
- BelvedereRevenueGrowthYoY
(RevenueFromContractWithCustomerExcludingAssessedTax 2026-07-04 / RevenueFromContractWithCustomerExcludingAssessedTax 2025-06-28) - 1
View filing- Source
- U.S. Securities and Exchange Commission
- Form
- 10-Q
- Period
- Jul 4, 2026
- Filed
- Aug 13, 2026
- Accession
- 0001628280-26-056493
- Concept
- CashAndCashEquivalentsAtCarryingValue
Disclosure
Belvedere Research publishes informational analysis. Nothing on this site is investment advice, an offer, or a solicitation to buy or sell any security.
This page is a company intelligence / data profile. It is not a research report unless a dated note is attached above. Rankings appearing here are independent of any issuer compensation.
Frequently asked questions
- What does National Vision Holdings, Inc. do?
- National Vision Holdings, Inc. (EYE) is a U.S. SEC registrant. The Commission classifies the issuer under SIC 3851 (Ophthalmic Goods).
- What industry is National Vision Holdings, Inc. in?
- National Vision Holdings, Inc. is classified in Healthcare (Ophthalmic Goods).
- When did National Vision Holdings, Inc. last file a periodic report?
- National Vision Holdings, Inc. last filed a 10-Q on Aug 13, 2026 (accession 0001628280-26-056493).
- What was National Vision Holdings, Inc.'s latest revenue?
- $498.8M for Q3 2026, sourced from 10-Q filed Aug 13, 2026.
- Does Belvedere cover National Vision Holdings, Inc.?
- National Vision Holdings, Inc. is in the Belvedere universe. Presence in the universe is not the same as active initiation coverage.